goserelin
teva pharma (new zealand) limited - goserelin acetate 12.5mg equivalent to 10.8 mg goserelin - subcutaneous implant - 10.8 mg - active: goserelin acetate 12.5mg equivalent to 10.8 mg goserelin excipient: poly(lactide) polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation.
goserelin
teva pharma (new zealand) limited - goserelin acetate 4.1mg equivalent to 3.6 mg goserelin - subcutaneous implant - 3.6 mg - active: goserelin acetate 4.1mg equivalent to 3.6 mg goserelin excipient: polyglactin - prostate cancer suitable for hormonal manipulation. adjuvant and neoadjuvant therapy in combination with radiotherapy for the management of locally advanced prostate cancer in men suitable for hormonal manipulation
zoladex la
astrazeneca (israel) ltd - goserelin as acetate - implant for injection - goserelin as acetate 10.8 mg/unit - goserelin - goserelin - prostate cancer suitable for hormonal manipulation.
zoladex
astrazeneca (israel) ltd - goserelin as acetate - implant - goserelin as acetate 3.6 mg/unit - goserelin - goserelin - treatment of prostate cancer suitable for hormonal manipulation. breast cancer in pre-menopausal women suitable for hormone manipulation.endometriosis. assisted reproduction: pituitary down regulation in preparion for superovulation. endometrial thinning: zoladex is indicated for the prethinning of the utetine endometrium prior ro endometrial ablation or resection. uterine fibroids: for reduction of fibroid size prior to surgery.
goserelin boston biopharma 10.8mg implant in a pre-filled syringe
boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - goserelin acetate - implant - goserelin acetate 10.8 milligram(s) - endocrine therapy
goserelin boston biopharma 3.6mg implant in a pre-filled syringe
boston biopharma limited malta life sciences park, building 2, level 0, san gwann sgn 3000, malta - goserelin acetate - implant - goserelin acetate 3.6 milligram(s) - endocrine therapy
goserelin uab boston biopharma lt 3.6 mg implant, in a pre-filled syringe
uab boston biopharma lt v.a. graiciuno g. 6-2 vilniaus m. sav. lt-02241, lithuania - goserelin acetate - implant - goserelin acetate 3.6 mg - endocrine therapy
goserelin uab boston biopharma lt 10.8 mg implant, in a pre-filled syringe
uab boston biopharma lt v.a. graiciuno g. 6-2 vilniaus m. sav. lt-02241, lithuania - goserelin acetate - implant - goserelin acetate 10.8 mg - endocrine therapy
zolacos cp combination goserelin 10.8mg (as acetate) implant syringe and bicalutamide 50mg tablet blister pack
astrazeneca pty ltd - goserelin, quantity: 10.8 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment
zolacos cp combination goserelin 3.6mg (as acetate) implant syringe and bicalutamide 50mg tablet blister pack
astrazeneca pty ltd - goserelin, quantity: 3.6 mg - implant - excipient ingredients: polyglactin - for the treatment of advanced prostate cancer. bicalutamide is also indicated for the prevention of disease flare associated with initial goserelin treatment.